Top Medical News
Antibiotic prophylaxis for primary penile implantation tied to higher infection risk
4 days ago
Antibiotic prophylaxis with vancomycin plus gentamicin alone for primary inflatable penile prosthesis surgery results in a higher risk of infection compared to nonstandard antibiotic regimens, suggests a recent study. On the other hand, antifungal use appears to reduce infection risk.
Chronic pelvic pain in men tied to severe sexual dysfunction
4 days ago
Men with urologic chronic pelvic pain syndrome (UCPPS) tend to suffer a more severe sexual dysfunction, including erectile (ED) and ejaculatory dysfunction, when compared to their healthy counterparts or patients with other chronic pain conditions, reveals a study.
Circulating 11-oxygenated androgens predict survival in localized prostate cancer
Stephen Padilla, 5 days ago
In men with localized prostate cancer undergoing radical prostatectomy and treated with 5α-reductase inhibitor (5-ARI), preoperative levels of circulating 11-oxygenated androgens can indicate either disease progression or improved survival, a recent study has found.
Bladder cycling pretransplant offers no clinical advantage in patients with defunctionalized bladder
24 Jan 2023
For patients with defunctionalized bladder, bladder cycling prior to renal transplant does little to improve outcomes such as postoperative urological complication, urodynamic criteria, and graft function and survival, according to a study.
MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden
Jairia Dela Cruz, 19 Jan 2023
Magnetic resonance imaging (MRI) guidance in stereotactic body radiotherapy (SBRT) for prostate cancer offers significant advantage over computed tomography (CT) guidance, with lower physician-scored toxic effects and patient-reported symptom burden, according to the results of the phase III MIRAGE* study.
Original New Drug Application Approvals by US FDA (01-15 January 2023)
17 Jan 2023
New drug applications approved by US FDA as of 01-15 January 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Regular marijuana use ups risk of overactive bladder
13 Jan 2023
Individuals who regularly use marijuana are at greater risk of having an overactive bladder, reveals a recent study in the US.
Special Reports
Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas. 
Conference Reports
Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
Roshini Claire Anthony, 25 Aug 2022

Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.

Is 5-year interval sufficient for prostate cancer screening in older men?
Roshini Claire Anthony, 18 Aug 2022

Diagnosis, progression, or death due to prostate cancer occur at approximately a decade to 15 years following an initial assessment of prostate-specific antigen (PSA) levels in older men, according to a study presented at EAU 2022.

Avelumab benefit may extend to cisplatin-unfit bladder cancer patients
Audrey Abella, 08 Aug 2022
The anti-PD-L1 antibody avelumab demonstrated clinical activity as first-line treatment for patients with metastatic or locally advanced urothelial carcinoma who were PD-L1-positive and ineligible for cisplatin, according to findings from the ARIES trial presented at EAU 2022.
Abiraterone-olaparib confers clinical benefit for mCRPC patients
Audrey Abella, 04 Aug 2022
The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.
Patients prefer being awake but sedated during urologic procedures
Elvira Manzano, 04 Aug 2022
Patients prefer conscious sedation over general anaesthesia (GA) during urologic procedures, according to Canadian researchers who followed patients undergoing various endourologic, ureteric, urethral, or advanced cystoscopic procedures.
Which drugs raise risk of urinary tract infections?
Stephen Padilla, 29 Jul 2022
Some medications may directly cause the occurrence of urinary tract infections (UTIs), and a recent study presented at the 37th Annual European Association of Urology Congress (EAU 2022) has identified six drugs that appear to contribute to “significant reporting levels” for infections.
SOUNDS: Real-world use affirms efficacy, safety of sacral neuromodulator device for OAB
Jairia Dela Cruz, 28 Jul 2022
Delivering electric stimulation to the sacral nerves using an implantable device appears to be safe and effective in the treatment of overactive bladder (OAB) in a real-world setting, according to the France-based SOUNDS study presented at the 37th Annual European Association of Urology Congress (EAU 2022).